Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SLN
SLN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SLN News
Bausch Health's Gradual Recovery Under Increased Scrutiny Following Lombard Odier's Stake Reduction
Dec 11 2025
NASDAQ.COM
Monday's Underperformers: Auto Dealerships and Biotechnology Shares
Nov 03 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for Silence Therapeutics, Keeps $75 Price Target Intact
Sep 16 2025
Benzinga
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 07 2025
Newsfilter
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
Jun 12 2025
Newsfilter
Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $35
May 09 2025
Benzinga
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
May 06 2025
Newsfilter
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
Mar 04 2025
Benzinga
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Kura Oncology (KURA) and Silence Therapeutics (SLN)
Feb 28 2025
Business Insider
Analysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Warby Parker (WRBY)
Feb 27 2025
Business Insider
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Feb 27 2025
Businesswire
Buy/Sell: Wall Street’s top 10 stock calls this week
Feb 14 2025
Business Insider
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Feb 13 2025
Businesswire
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Feb 11 2025
Benzinga
Goldman Sachs Initiates Coverage On Silence Therapeutics with Sell Rating, Announces Price Target of $6
Feb 11 2025
Benzinga
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Jan 29 2025
Benzinga
Show More News
